This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hülsmann, M. Articles by Pacher, R. Search for Related Content PubMed PubMed Citation Articles by Hülsmann, M. Articles by Pacher, R.

Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure

Martin Hülsmann, MD^*, Brigitte Stanek, MD^*, Bernhard Frey, MD^*, Barbara Sturm, MD^*, Dinah Putz, MD^**, Thomas Kos, MD^*, Rudolf Berger, MD^*, Wolfgang Woloszczuk, PhD, Gerald Maurer, MD, FACC^* and Richard Pacher, MD^{* **}

^* Department of Cardiology, University of Vienna, Vienna, Austria
^** Department of Nephrology, University of Vienna, Vienna, Austria
Department of Ludwig Boltzmann Institute for Experimental Endocrinology, University of Vienna, Vienna, Austria

View larger version (15K): [in a new window]   Figure 1 Plasma concentrations of norepinephrine, ANP and big ET-1 in 149 1-year survivors (black bars) and 69 patients who died or were transplanted under priority status (empty bars). Values are mean ± SD.

View larger version (13K): [in a new window]   Figure 2 Kaplan-Meier analysis showing cumulative rates of event-free survival in 218 patients with chronic heart failure stratified in two groups based on big-ET-1 plasma concentration. Patients with plasma big-ET levels 4.3 fmol/ml differed significantly from patients with lower big-ET concentrations.